Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
October 18th, 2018
8K views
Spontaneously contracting syncytia of cardiomyocytes derived from human-induced pluripotent stem cells are useful models of human cardiac physiology and pharmacology. Here we present a high-throughput screening system to quantify the effects of exogenous compounds on beating frequency, using a Ca-sensitive fluorescent dye and a temperature-controlled imaging multi-well plate reader.
Overview
This study presents a high-throughput screening system for quantifying the effects of compounds on the beating frequency of spontaneously contracting syncytia derived from human-induced pluripotent stem cell cardiomyocytes. The method aims to address critical questions in cardiac safety pharmacology.
Key Study Components
Area of Science
- Cardiac safety pharmacology
- Stem cell-derived cardiomyocytes
- High-throughput screening methods
Background
- Human-induced pluripotent stem cells can be differentiated into cardiomyocytes.
- Syncytia of cardiomyocytes serve as models for studying cardiac physiology.
- Evaluating the impact of drugs on cardiac rhythm is crucial for safety assessments.
- High-throughput techniques allow for rapid evaluation of multiple compounds.
Purpose of Study
- To develop a method for assessing the effects of compounds on cardiomyocyte contractions.
- To provide a cost-effective approach for screening large numbers of drugs.
- To enhance understanding of how new medications may alter cardiac rhythms.
Methods Used
- Thawing and culturing human-induced pluripotent stem cell-derived cardiomyocytes.
- Using a temperature-controlled imaging multi-well plate reader.
- Employing a calcium-sensitive fluorescent dye to measure contractions.
- Recording and analyzing the effects of various compounds on beating frequency.
Main Results
- Demonstrated that blockers of cardiac ion channels significantly affect cardiomyocyte rhythm.
- Amlodipine increased beating frequency in a concentration-dependent manner.
- E-4031 and tetrodotoxin decreased the rhythm, with specific concentration thresholds.
- Bepridil exhibited an all-or-nothing effect, indicating its primary action on sodium channels.
Conclusions
- The developed method is effective for rapid screening of cardiac safety pharmacology.
- It provides insights into the effects of various compounds on cardiac rhythm.
- This approach can facilitate the evaluation of new therapeutic agents for cardiac safety.
Frequently Asked Questions
What are syncytia of cardiomyocytes?
Syncytia are multinucleated cells formed by the fusion of individual cardiomyocytes, allowing for coordinated contractions.
How does the high-throughput screening system work?
It quantifies the effects of compounds on the beating frequency of cardiomyocytes using a plate reader and fluorescent dye.
What is the significance of using human-induced pluripotent stem cells?
They provide a human-relevant model for studying cardiac physiology and pharmacology.
What types of compounds were tested in the study?
Various blockers of cardiac ion channels were tested to assess their effects on rhythm.
What are the implications of this research?
It aids in understanding drug interactions with cardiac rhythms, which is crucial for drug safety evaluations.
How long does the culturing process take?
The cardiomyocytes are cultured for three to four weeks before testing.
Executive Industry Relevance
High-throughput quantification of compound effects on human iPSC-derived cardiomyocyte syncytia addresses a critical need in early cardiac safety pharmacology. This assay enables rapid, physiologically relevant assessment of drug-induced changes in cardiac rhythm, supporting predictive confidence and de-risking at the discovery and lead optimization stages. Integration of scalable, quantitative readouts informs portfolio triage and reduces late-stage cardiac liability risk.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of compound effects on human cardiac electrophysiology using disease-relevant cell systems.
- Supports mechanistic de-risking by quantifying ion channel modulator impact on cardiomyocyte rhythm.
- Facilitates functional target validation for cardiac safety endpoints in preclinical candidate selection.
Screening & Assay Development
- Delivers standardized, reproducible high-throughput screening of compound libraries in 384-well format.
- Generates quantitative, time-resolved measurements of beating frequency for robust assay outputs.
- Prepares validated biological systems for downstream safety and efficacy profiling workflows.
Translational & Preclinical Research
- Aligns in vitro cardiac safety data with translational biomarker strategies for human risk assessment.
- Provides continuity from early discovery through preclinical safety evaluation using human-relevant models.
- Enables risk-adjusted advancement decisions based on predictive cardiac liability data.
Pipeline & Workflow Integration
This assay positions within the discovery-to-preclinical continuum, enabling early detection of cardiac risk and supporting lead identification and optimization decisions.
- Discovery Biology: Quantifies drug-induced modulation of cardiac rhythm to clarify mechanistic risk.
- Screening: Offers reproducible, scalable assay readiness for large compound sets.
- Analytics: Provides quantitative beating frequency outputs for comparative analysis across conditions and time points.
- Translational Research: Bridges in vitro findings to preclinical safety endpoints using human iPSC-derived models.
- Enterprise Reuse: Establishes a reusable, standardized platform for ongoing cardiac safety screening across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in cardiac safety and reduces mechanistic ambiguity for new chemical entities.
- Operational Value: Enables assay standardization, reproducibility, and high-throughput scalability in 384-well format.
- Strategic Value: Supports informed go/no-go decisions and capital efficiency by identifying cardiac liabilities early.
- Portfolio Impact: Improves risk-adjusted prioritization and advancement of candidates with favorable cardiac profiles.
Implementation Considerations
- Requires expertise in hiPSC-cardiomyocyte culture and handling of fragile syncytia.
- Needs access to temperature-controlled imaging plate readers and compatible data analysis software.
- Demands rigorous cross-team standardization of assay setup and data processing protocols.
- Adaptation may be needed for different compound classes or model system variants.
- Careful pipetting and biosafety precautions are essential due to cell and compound sensitivity.
Biopharma FAQs
Why does null hypothesis testing matter for cardiac rhythm quantification?
Null hypothesis testing enables objective determination of whether observed changes in beating frequency after compound addition are statistically significant, supporting robust target validation and risk assessment in cardiac safety pharmacology.
How does independent variable isolation fit the 384-well screening workflow?
Isolating each compound as an independent variable in separate wells ensures that observed effects on cardiomyocyte rhythm can be attributed directly to specific test agents, enhancing interpretability and discovery pipeline confidence.
What do quantitative beating frequency measurements enable in drug evaluation?
Quantitative measurements of beating frequency provide precise, reproducible endpoints for comparing compound effects, enabling data-driven prioritization and de-risking of candidates with potential cardiac liabilities.
Why are replication requirements critical for cross-functional cardiac safety teams?
Replication across wells and plates ensures assay reproducibility and reliability, facilitating cross-functional collaboration and consensus on cardiac risk decisions throughout the R&D organization.
Which statistical analysis capabilities are required before implementing this assay?
Robust statistical tools are needed to analyze time-resolved beating frequency data, compare baseline and post-compound conditions, and support decision-making thresholds for cardiac safety screening.
